Predict your next investment

Public-Private Partnership
wellcome.ac.uk

See what CB Insights has to offer

Investments

155

Portfolio Exits

44

Funds

2

Partners & Customers

10

Service Providers

1

About Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving improvements in human and animal health. The company supports biomedical research and the medical humanities, including public engagement, education and the application of research to improve health. Funding focuses on supporting outstanding research, accelerating the application of research and exploring medicine in historical and cultural contexts.

Wellcome Trust Headquarter Location

Gibbs Building 214 Euston Road

London, England, NW1 2BE,

United Kingdom

44-0-20-7611-8888

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Wellcome Trust

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Wellcome Trust in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Wellcome Trust News

10:00 EDT Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance

Jun 21, 2022

News provided by Share this article Leading pharmaceutical companies join Vivli's new global register to accelerate research into antibiotic resistant bacteria CAMBRIDGE, Mass., June 21, 2022 /PRNewswire/ -- The Antimicrobial Resistance Register , unveiled today by the nonprofit organization Vivli, makes it possible for biopharmaceutical companies to share susceptibility data on infection causing pathogens for the first time ever in one online platform, marking a critical step in combating the growing global health threat of antimicrobial resistance. With the active participation from leading pharmaceutical and biotech enterprises, researchers will be able to use the AMR Register to translate masses of antimicrobial resistance surveillance data into meaningful action that saves lives and preserves antibiotics for future generations. Infections caused by antimicrobial-resistant bacteria are on the rise after years of overprescribing antibiotics. Now, illnesses that were once easily treatable with antibiotics are becoming more difficult to cure, and infections caused by antibiotic-resistant bacteria cost billions in avoidable healthcare dollars. According to latest figures from the GRAM report, almost 5 million people died worldwide with an antimicrobial resistant infection. If left unchecked, the scale of antimicrobial resistance will quickly outpace what we have experienced with COVID-19, with deaths rising to 10 million per year by 2050, according to the United Nations. Biopharmaceutical companies routinely conduct surveillance on all new antimicrobials to monitor susceptibility to pathogens of interest, generating large volumes of high-quality data. Currently, there is no easy way for researchers to access this raw data or combine and analyze multiple datasets from industry. The AMR register will make it easy for pharmaceutical organizations to securely share their data with researchers, national governments, and multi-lateral organizations such as the United Nations, CDC and the World Health Organization. With robust, reliable industry data, all accessible in one place, scientists will be able to better map key patterns of resistance and identify the emergence of new antibiotic resistant pathogens. Research insights will also inform decision-making around use of antimicrobials, shape policies aimed at halting the spread of resistant pathogens, and spur innovation around new antimicrobial drugs. "Our understanding of how to control antimicrobial resistant infections and how best to protect human health hinges on better access to surveillance data. Now, with the AMR Register we have an early warning system for one of the greatest public health threats we face," said Chair of the AMR Register Scientific Advisory Board Marc Mendelson, PhD, Professor of Infectious Diseases and Head of the Division of Infectious Diseases & HIV Medicine at Groote Schuur Hospital, University of Cape Town. "Biopharmaceutical company data is a vital missing link in AMR surveillance, making the research enabled by the AMR register critical to mitigating the AMR pandemic and protecting the effectiveness of antibiotics, now and in the future." Companies that have committed to contributing their data to the AMR Register include Pfizer, GSK, Johnson & Johnson, Merck, Paratek, Shionogi & Co., Ltd., and Venatorx Pharmaceuticals. Viatris have joined as a supporter of the AMR register." In 2016, over 100 biopharmaceutical companies and trade associations signed The Davos Declaration on Antibiotic Resistance and later released the Industry Roadmap for Progress on Combating Antimicrobial Resistance ahead of the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance, committing to sharing surveillance data to make it accessible to public health bodies and healthcare professionals. With the AMR Register, industry can now fulfill those commitments, helping contain the risk of AMR and advance scientific knowledge. "We need urgent action to avert a wave of antibiotic-resistant bacteria," said Vivli's Executive Director Rebecca Li, PhD. "By making data openly available, industry is making a crucial contribution to furthering science and helping us get ahead of the next pandemic." The AMR Register is guided by a Scientific Advisory Board of influential leaders in antimicrobial resistance and global health, including Henry Kajumbula , MD of Makerere University College of Health Sciences; Trudie Lang of the Nuffield Department of Medicine; Marc Mendelson, PhD, of Groote Schuur Hospital, University of Cape Town; Arjun Srinivasan, MD, from the Centers for Disease Control and Prevention; Janet Midega, PhD, from Wellcome; and Andy Stergachis , PhD, of the University of Washington. The AMR Register was made possible with an initial seed grant from the Wellcome Trust. Learn more at www.amr.vivli.org About Vivli Vivli is a non-profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. Data sharing initiatives include the  Antimicrobial Resistance Register  for AMR surveillance data and the Vivli Platform  for clinical trial data. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community. For more information, visit www.vivli.org  and follow us on Twitter @VivliCenter . About Wellcome Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we're taking on three worldwide health challenges: mental health, infectious disease and climate and health. Contact:

Wellcome Trust Investments

155 Investments

Wellcome Trust has made 155 investments. Their latest investment was in Generate Capital as part of their Private Equity on July 7, 2021.

CBI Logo

Wellcome Trust Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/19/2021

Private Equity

Generate Capital

$2,000M

Yes

17

4/21/2021

Grant - VIII

Oxitec

$6.8M

Yes

8

7/27/2020

Seed VC

Transformative AI

$1.7M

Yes

10

6/3/2020

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

4/23/2020

Grant

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/19/2021

4/21/2021

7/27/2020

6/3/2020

4/23/2020

Round

Private Equity

Grant - VIII

Seed VC

Private Equity

Grant

Company

Generate Capital

Oxitec

Transformative AI

Subscribe to see more

Subscribe to see more

Amount

$2,000M

$6.8M

$1.7M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

17

8

10

10

10

Wellcome Trust Portfolio Exits

44 Portfolio Exits

Wellcome Trust has 44 portfolio exits. Their latest portfolio exit was Point A Hotels on April 05, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/5/2022

Shareholder Liquidity

Point A Hotels

$99M

1

9/6/2021

Acquired

$99M

3

8/18/2021

Acquired

$99M

2

5/4/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/11/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/5/2022

9/6/2021

8/18/2021

5/4/2021

1/11/2021

Exit

Shareholder Liquidity

Acquired

Acquired

Acquired

Acquired

Companies

Point A Hotels

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

3

2

10

10

Wellcome Trust Acquisitions

2 Acquisitions

Wellcome Trust acquired 2 companies. Their latest acquisition was Urban & Civic on October 28, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/28/2021

Growth Equity

$99M

Take Private

3

5/13/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/28/2021

5/13/2015

Investment Stage

Growth Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Take Private

Subscribe to see more

Sources

3

10

Wellcome Trust Fund History

2 Fund Histories

Wellcome Trust has 2 funds, including Health Innovation Challenge Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/29/2014

Health Innovation Challenge Fund

1

Wellcome Trust Leap Fund

10

Closing Date

7/29/2014

Fund

Health Innovation Challenge Fund

Wellcome Trust Leap Fund

Fund Type

Status

Amount

Sources

1

10

Wellcome Trust Partners & Customers

10 Partners and customers

Wellcome Trust has 10 strategic partners and customers. Wellcome Trust recently partnered with ripeta on September 9, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

9/8/2020

Partner

Wellcome and Ripeta partner to assess dataset availability in funded research - Digital Science

Wellcome Trust and Ripeta partner to assess dataset availability in funded research .

1

6/24/2020

Partner

United States

Pfizer : and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa

This release contains forward-looking information about the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance , a new multi-year , public-private research collaboration with the governments of Ghana , Kenya , Malawi and Uganda to track resistance patterns and better understand the burden of antimicrobial resistance on patients living in low - and middle-income countries , including its potential benefits , that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements .

4

12/2/2019

Partner

Germany

Wellcome Trust establishes first Translational Partnership in Germany - with the BIH and Charité

The overarching aim of the translational partnership between the Wellcome Trust and the Berlin Institute of Health is to effect a change in research culture , thus maximizing the possibilities for translational medicine to benefit patients and society at large .

1

11/25/2019

Partner

Belgium

Subscribe to see more

Subscribe to see more

10

7/8/2019

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

9/8/2020

6/24/2020

12/2/2019

11/25/2019

7/8/2019

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

Germany

Belgium

United Kingdom

News Snippet

Wellcome and Ripeta partner to assess dataset availability in funded research - Digital Science

Wellcome Trust and Ripeta partner to assess dataset availability in funded research .

Pfizer : and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa

This release contains forward-looking information about the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance , a new multi-year , public-private research collaboration with the governments of Ghana , Kenya , Malawi and Uganda to track resistance patterns and better understand the burden of antimicrobial resistance on patients living in low - and middle-income countries , including its potential benefits , that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements .

Wellcome Trust establishes first Translational Partnership in Germany - with the BIH and Charité

The overarching aim of the translational partnership between the Wellcome Trust and the Berlin Institute of Health is to effect a change in research culture , thus maximizing the possibilities for translational medicine to benefit patients and society at large .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

4

1

10

10

Wellcome Trust Service Providers

1 Service Provider

Wellcome Trust has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Wellcome Trust Team

4 Team Members

Wellcome Trust has 4 team members, including current Chief Financial Officer, Simon Jeffreys.

Name

Work History

Title

Status

Stewart Newton

Founder

Current

Simon Jeffreys

Chief Financial Officer

Current

Tim Livett

Chief Financial Officer

Current

Gary Steinberg

Chief Investment Officer

Former

Name

Stewart Newton

Simon Jeffreys

Tim Livett

Gary Steinberg

Work History

Title

Founder

Chief Financial Officer

Chief Financial Officer

Chief Investment Officer

Status

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.